Sign up to save your podcasts
Or
Share Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Host: Ryan Quigley
In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
View all episodes
By ReachMD
4.5
22 ratings
Host: Ryan Quigley
In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.